Investment firm Baird has adjusted its outlook on Qiagen (QGEN, Financial), raising the price target from $42 to $43. This adjustment comes as the firm revises its model in anticipation of Qiagen's upcoming first-quarter financial results.
While the price target saw a slight increase, Baird maintains its Neutral rating on the stock. The decision reflects a cautious yet incrementally positive stance as investors await further insights from Qiagen's performance in the coming quarter.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 16 analysts, the average target price for Qiagen NV (QGEN, Financial) is $49.71 with a high estimate of $55.00 and a low estimate of $43.00. The average target implies an upside of 22.11% from the current price of $40.71. More detailed estimate data can be found on the Qiagen NV (QGEN) Forecast page.
Based on the consensus recommendation from 18 brokerage firms, Qiagen NV's (QGEN, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Qiagen NV (QGEN, Financial) in one year is $46.95, suggesting a upside of 15.33% from the current price of $40.71. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Qiagen NV (QGEN) Summary page.
